IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
R&D Pipeline Products
Product Class Date Terms of Agreement
GVAX V/L 2008 Cell Genesys licensed ww rights of GVAX
(immunotherapy of allogeneic cancer cell lines, modified
to secrete GM-CSF (granulocyte macrophage-colony
stimulating factor ) for prostate cancer to Takeda for
$50m upfront and milestones of up to $270m in the USA,
EU and Japan in addition to royalties. Takeda will pay all
ongoing development and commercialization costs with
Cell Genesys responsible for ww manufacture and supply,
while retaining rights to co-promote GVAX for prostate
cancer in the USA. In December 2008 Takeda terminated
development with all commercial rights to be returned to
Cell Genesys who will receive wind-down payments
associated with the phasing out of the remaining clinical
development activities.
Motesanib (AMG 706) L 2008 Takeda has obtained rights from Amgen to exclusively
develop and market the anticancer drug motesanib (AMG
706) in Japan and co-develop and co-market with Amgen
Inc outside of Japan. Takeda will pay $100m upfront and
pay 100% of development in Japan and 60% overseas,
in addition to milestone payments of up to Yen175m as
well as royalties.
12 compounds — 2008 Takeda has obtained exclusive rights to 12 biologic
compounds from Amgen warranting an upfront payment
of $2million, payment of all development costs in Japan
as well as a percentage overseas, totaling up to $340m
and potentially another Yen362m in milestones and then
royalties on sales.
TAK 652. and TAK 220 J 2007 Tobira acquired exclusive worldwide rights from Takeda
to develop, manufacture and commercialize TAK 220 and
TAK 652. Further details of the agreement were not
disclosed. Both agents are oral CCR5 antagonists for HIV
in phase I in Europe and the USA. Tobira plans to start
phase II trials of TAK 652, with TAK 220 being developed
as a back-up.
© 2009 IMS Health In cor po rated or its af fil i ates Page 95